切换至 "中华医学电子期刊资源库"

第五届中国出版政府奖音像电子网络出版物奖提名奖

中国科技核心期刊

中国科学引文数据库(CSCD)来源期刊

中华重症医学电子杂志 ›› 2026, Vol. 12 ›› Issue (03) : 219 -234. doi: 10.3877/cma.j.issn.2096-1537.2026.03.001

专家共识

重症患者侵袭性丝状真菌病诊断与治疗专家共识
黄英姿, 谢剑锋, 孙骎, 余跃天, 郑瑞强, 席寅, 陈轶坚, 杜小幸, 余进, 杨婧, 苏欣, 邵华, 黄丽丽, 黎丽芬, 吴昌德, 吴骎, 徐静媛, 杨文杰, 张俊丽, 张曦文, 周梦兰, 王明贵†(), 俞云松†(), 邱海波†(), 《重症患者侵袭性丝状真菌病诊断与治疗专家共识》专家组   
  • 收稿日期:2026-06-01 出版日期:2026-08-28
  • 通信作者: 王明贵, 俞云松, 邱海波
  • 基金资助:
    国家科技重大专项(2023ZD0506500,2025ZD01902704)

Expert consensus on the diagnosis and treatment of invasive filamentous fungal infections in critically ill patients

Yingzi Huang, Jianfeng Xie, Qin Sun   

  • Received:2026-06-01 Published:2026-08-28
引用本文:

黄英姿, 谢剑锋, 孙骎, 余跃天, 郑瑞强, 席寅, 陈轶坚, 杜小幸, 余进, 杨婧, 苏欣, 邵华, 黄丽丽, 黎丽芬, 吴昌德, 吴骎, 徐静媛, 杨文杰, 张俊丽, 张曦文, 周梦兰, 王明贵, 俞云松, 邱海波, 《重症患者侵袭性丝状真菌病诊断与治疗专家共识》专家组. 重症患者侵袭性丝状真菌病诊断与治疗专家共识[J/OL]. 中华重症医学电子杂志, 2026, 12(03): 219-234.

Yingzi Huang, Jianfeng Xie, Qin Sun. Expert consensus on the diagnosis and treatment of invasive filamentous fungal infections in critically ill patients[J/OL]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2026, 12(03): 219-234.

表1 GRADE分级标准
表2 重症非粒缺患者常见丝状真菌感染危险因素[16,19,20,21]
表3 侵袭性丝状真菌病临床特征
疾病类型 临床特征
侵袭性曲霉病 肺部是主要受累部位,常表现为发热、咳嗽、气促、胸膜炎性胸痛和咯血;非粒缺患者早期常为气道侵袭型改变,如持续咳嗽、喘息、痰栓形成和呼吸困难,需注意侵袭性气管支气管曲霉病的可能;鼻窦-眼眶受累时可表现为鼻塞、面部疼痛或肿胀、鼻出血、嗅觉减退;严重时可出现眼眶受累症状,如眼球突出、视力下降;中枢神经系统受累时表现为头痛、癫痫发作、局灶性神经功能缺损(如偏瘫、失语)、意识水平改变等;播散性感染时症状取决于受累器官,可包括高热、多器官功能衰竭等
毛霉病 鼻-眶-脑毛霉病早期可有发热、面痛、鼻塞、血性或黑色鼻分泌物、鼻腭黑痂;累及眼眶后可出现眼睑肿胀、眼球突出、复视、眼肌麻痹和视力下降;颅内受累时可出现意识障碍、颅神经损害等;肺毛霉病可表现为持续高热、咳嗽、胸痛、呼吸困难和咯血;因其血管侵袭性强,严重者可发生大咯血;胃肠道毛霉病可表现为腹痛、恶心、呕吐、呕血、腹部压痛、便血、黑便、腹胀等;播散性毛霉病常由肺或鼻脑型播散引起,可出现多发性器官受累的相应症状
侵袭性镰刀菌病 肺部受累,与侵袭性肺曲霉病类似,可有发热、咳嗽、胸痛和呼吸困难;血流(真菌血症,发生率为40%~60%,显著高于其他丝状真菌病)、骨关节、中枢神经系统等多部位受累时可形成播散性感染
表4 侵袭性丝状真菌病影像学特征
表5 GM试验在重症非粒缺患者诊断IA中的应用建议[12]
表6 ICU患者侵袭性丝状真菌病诊断标准[19]
表7 IPA患者初始治疗建议
表8 侵袭性镰刀菌病及其他丝状真菌病治疗建议
表9 肥胖患者抗丝状真菌药物应用建议
表10 肝功能损伤患者抗丝状真菌感染药物剂量调整建议
表11 肾功能损伤患者抗丝状真菌感染药物剂量调整建议
表12 临床常用抗丝状真菌药物在CRRT时的剂量调整策略
表13 抗丝状真菌药物与重症患者常用药物的DDI影响及管理建议
抗丝状真菌药物 抗微生物药物 抗肿瘤药物 皮质醇和肾上腺皮质激素 免疫抑制剂 抗凝药 降糖药 质子泵抑制剂
艾沙康唑 禁止与利福布汀、利福平联合 可能导致浓度增加,应密切监测,并在需要时减少剂量 密切监测 他克莫司剂量减少21%;与环孢素、西罗莫司联合时密切监测 - - -
伏立康唑 与氟喹诺酮类药物联合可能延长QT间期,增加心律失常风险,应密切监测。禁止与利福布汀、利福平联合 避免与伊立替康、依维莫司、克唑替尼联合 密切监测 环孢素剂量减半,他克莫司减至初始剂量的1/3,禁止与西罗莫司联合 可能增加出血风险,应谨慎联合 避免与西格列汀联合;与那格列奈、瑞格列奈联合时可能造成低血糖,应密切监测 增加神经系统不良反应发生风险,联合应用时建议减少质子泵抑制剂剂量
泊沙康唑 与氟喹诺酮类药物联合可能延长QT间期,增加心律失常风险,应密切监测。禁止与利福布汀、利福平联合 避免与伊立替康、依维莫司、克唑替尼联合 密切监测 环孢菌素减至初始剂量的3/4左右,他克莫司减至初始剂量的1/3左右,一般情况下禁止与西罗莫司联合* 禁止与利伐沙班联合;与华法林联合时需谨慎 避免与西格列汀联合;与那格列奈、瑞格列奈联合时可能造成低血糖,应密切监测 避免与口服混悬液联合使用
两性霉素B制剂 氨基糖苷类、多黏菌素、万古霉素等联合可能会增加肾毒性;应密切监测 可能增加肾毒性、支气管痉挛和低血压风险;应谨慎联合 可加重诱发低血钾;不推荐联合 无需调整剂量,但需重视监测肾功能 可能增加出血及肾毒性风险;应密切监测 加强肾功能监测 -
表14 抗丝状真菌药物的TDM管理建议
表15 IPA的疗效评估
1
Rafique A, Sharmin S, Raj A, et al. Comparative overview of Aspergillus fumigatus, A. flavus, and A. niger: pathogenicity, resistance, and public health significance[J]. J Infect Public Health, 2026, 19(2): 103070.
2
张丽, 康梅, 陈中举, 等. 我国霉菌感染流行病学分析: 多中心回顾性研究[J]. 协和医学杂志, 2023, 14(3): 559-565.
3
Sedik S, Wolfgruber S, Hoenigl M, et al. Diagnosing fungal infections in clinical practice: a narrative review[J]. Expert Rev Anti Infect Ther, 2024, 22(11): 935-949.
4
Prattes J, Giacobbe DR, Marelli C, et al. Posaconazole for prevention of COVID-19-associated pulmonary aspergillosis in mechanically ventilated patients: a European multicentre case-control study (POSACOVID)[J]. Mycoses, 2025, 68(1): e70023.
5
Cao Y, Li Y, Wang M, et al. Epidemiological shifts and advances in research on early diagnosis of invasive fungal infection in critically ill patients[J]. Front Cell Infect Microbiol, 2025, 15: 1658476.
6
van Rhijn N, Rhodes J. Evolution of antifungal resistance in the environment[J]. Nat Microbiol, 2025, 10(8): 1804-1815.
7
Pfaller MA, Carvalhaes CG, Castanheira M. Susceptibility patterns of amphotericin B, itraconazole, posaconazole, voriconazole and caspofungin for isolates causing invasive mould infections from the SENTRY Antifungal Surveillance Program (2018-2021) and application of single-site epidemiological cutoff values to evaluate amphotericin B activity[J]. Mycoses, 2023, 66(10): 854-868.
8
徐媛, 陈敏, 廖万清. 中国侵袭性曲霉菌病流行病学现状[J]. 中国真菌学杂志, 2018, 13(1): 57-60.
9
Krifors A, Blennow O, Påhlman LI, et al. Influenza-associated invasive aspergillosis in patients admitted to the intensive care unit in Sweden: a prospective multicentre cohort study[J]. Infect Dis (Lond), 2024, 56(2): 110-115.
10
Xia LJ, Hou TT, Liu XL, et al. Impact of physician awareness and microbiological examination on incidence of COVID-19-associated pulmonary aspergillosis: a retrospective study[J]. BMC Pulm Med, 2025, 25(1): 198.
11
Feys S, Carvalho A, Clancy CJ, et al. Influenza-associated and COVID-19-associated pulmonary aspergillosis in critically ill patients[J].Lancet Respir Med, 2024, 12(9): 728-742.
12
Denning DW. Global incidence and mortality of severe fungal disease[J]. Lancet Infect Dis, 2024, 24(7): e428-e438.
13
Mahalaxmi I, Jayaramayya K, Venkatesan D, et al. Mucormycosis: an opportunistic pathogen during COVID-19[J]. Environ Res, 2021, 201: 111643.
14
Feys S, Lagrou K, Lauwers HM, et al. High burden of COVID-19-associated pulmonary aspergillosis in severely immunocompromised patients requiring mechanical ventilation[J]. Clin Infect Dis, 2024, 78(2): 361-370.
15
Kontoyiannis DP, Walsh TJ. Mucormycosis[J]. N Engl J Med, 2026, 394(7): 684-698.
16
Demonchy J, Biard L, Clere-Jehl R, et al. Multicenter retrospective study of invasive Fusariosis in Intensive Care Units, France[J]. Emerg Infect Dis, 2024, 30(2): 215-224.
17
Sheng M, Ritchie B, Afshari Mirak S, et al. Review of Fusariosis in patients with hematologic malignancies[J]. Radiol Imaging Cancer, 2025, 7(6): e250174.
18
潘月秋, 黄昉芳, 卫建华, 等. 1例心脏移植术后并发下肢侵袭性镰刀菌感染患者的护理[J]. 中华护理杂志, 2025, 60(22): 2762-2766.
19
Nucci M, Anaissie E. Invasive fusariosis[J]. Clin Microbiol Rev, 2023, 36(4): e0015922.
20
Pérez-Nadales E, Alastruey-Izquierdo A, Linares-Sicilia MJ, et al. Invasive Fusariosis in nonneutropenic patients, Spain, 2000-2015[J]. Emerg Infect Dis, 2021, 27(1): 26-35.
21
Agrawal R, Yeldandi A, Savas H, et al. Pulmonary Mucormycosis: risk factors, radiologic findings, and pathologic correlation[J]. Radiographics, 2020, 40(3): 656-666.
22
Janssens I, Lambrecht BN, Van Braeckel E. Aspergillus and the lung[J]. Semin Respir Crit Care Med, 2024, 45(1): 3-20.
23
He H, Ding L, Li F, et al. Clinical features of invasive bronchial-pulmonary aspergillosis in critically ill patients with chronic obstructive respiratory diseases: a prospective study[J]. Crit Care, 2011, 15(1): R5.
24
Desai SM, Gujarathi-Saraf A, Agarwal EA. Imaging findings using a combined MRI/CT protocol to identify the "entire iceberg" in post-COVID-19 mucormycosis presenting clinically as only "the tip"[J]. Clin Radiol, 2021, 76(10): 784.e27-784.e33.
25
Ghuman SS, Sindhu P, Buxi T, et al. CT appearance of gastrointestinal tract mucormycosis[J]. Abdom Radiol (NY), 2021, 46(5): 1837-1845.
26
Marom EM, Holmes AM, Bruzzi JF, et al. Imaging of pulmonary Fusariosis in patients with hematologic malignancies[J]. AJR Am J Roentgenol, 2008, 190(6): 1605-1609.
27
Middlebrooks EH, Frost CJ, De Jesus RO, et al. Acute invasive fungal rhinosinusitis: a comprehensive update of CT findings and design of an effective diagnostic imaging model[J]. AJNR Am J Neuroradiol, 2015, 36(8): 1529-1535.
28
Erami M, Aboutalebian S, Hashemi Hezaveh SJ, et al. Invasive Fusarium rhinosinusitis in COVID-19 patients: report of three cases with successful management[J]. Front Cell Infect Microbiol, 2023, 13: 1247491.
29
张英芳, 黄琳娜, 詹庆元, 等. 重症监护室中侵袭性肺曲霉菌病的诊断标准: 因人而异[J]. 内科急危重症杂志, 2022, 28(5): 361-367.
30
Bassetti M, Azoulay E, Kullberg BJ, et al. EORTC/MSGERC definitions of invasive fungal diseases: summary of activities of the Intensive Care Unit Working Group[J]. Clin Infect Dis, 2021, 72(Suppl 2): S121-S127.
31
Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of Mucormycosis: an update[J]. J Fungi (Basel), 2020, 6(4): 265.
32
中华人民共和国国家卫生健康委员会. 侵袭性真菌病实验诊断标准[EB/OL]. (2026-04-30) [2026-05-25].
33
Alam F, Siddiqui B, Hasan N, et al. Rapid cytological diagnosis with evaluation of pre- and post-therapeutic fungal morphological characteristics in Mucormycosis[J]. J Clin Med Res, 2023, 15(1): 31-37.
34
Yang J, Wu X, Zhang Q, et al. Metagenomic next-generation sequencing and galactomannan testing for the diagnosis of invasive pulmonary aspergillosis[J]. Sci Rep, 2024, 14(1): 31389.
35
Blot S, Rello J, Koulenti D. Diagnosing invasive pulmonary aspergillosis in ICU patients: putting the puzzle together[J]. Curr Opin Crit Care, 2019, 25(5): 430-437.
36
中华医学会检验医学分会临床微生物学组. 侵袭性真菌病实验室诊断指南[J]. 中华检验医学杂志, 2022, 45(2): 119-126.
37
Tsotsolis S, Kotoulas SC, Lavrentieva A. Invasive pulmonary aspergillosis in coronavirus disease 2019 patients lights and shadows in the current landscape[J]. Adv Respir Med, 2023, 91(3): 185-202.
38
Tuon FF. A systematic literature review on the diagnosis of invasive aspergillosis using polymerase chain reaction (PCR) from bronchoalveolar lavage clinical samples[J]. Rev Iberoam Micol, 2007, 24(2): 89-94.
39
Sun W, Wang K, Gao W, et al. Evaluation of PCR on bronchoalveolar lavage fluid for diagnosis of invasive aspergillosis: a bivariate Meta-analysis and systematic review[J]. PLoS One, 2011, 6(12): e28467.
40
Lamoth F, Kontoyiannis DP. PCR diagnostic platforms for non-Aspergillus mold infections: ready for routine implementation in the clinic?[J]. Expert Rev Mol Diagn, 2024, 24(4): 273-282.
41
Liu X, Song Y, Li R. The use of combined PCR, fluorescence in situ hybridisation and immunohistochemical staining to diagnose mucormycosis from formalin-fixed paraffin-embedded tissues[J]. Mycoses, 2021, 64(12): 1460-1470.
42
Gholinejad-Ghadi N, Shokohi T, Seifi Z, et al. Identification of Mucorales in patients with proven invasive mucormycosis by polymerase chain reaction in tissue samples[J]. Mycoses, 2018, 61(12): 909-915.
43
Han Y, Wu X, Jiang G, et al. Bronchoalveolar lavage fluid polymerase chain reaction for invasive pulmonary aspergillosis among high-risk patients: a diagnostic meta-analysis[J]. BMC Pulm Med, 2023, 23(1): 58.
44
Lamoth F, Akan H, Andes D, et al. Assessment of the Role of 1, 3-β-d-Glucan Testing for the Diagnosis of Invasive Fungal Infections in Adults[J]. Clin Infect Dis, 2021, 72(Suppl 2): S102-S108.
45
郭景景, 李钦峰, 吴海华, 等.(1, 3)-β-D葡聚糖、半乳甘露聚糖联合降钙素原检测对侵袭性真菌感染的诊断价值[J].国际免疫学杂志, 2020, 43(1): 31-36.
46
Egger M, Prüller F, Krause R, et al. Utility of serum 1, 3-β-d-glucan testing for diagnosis and prognostication in COVID-19-associated pulmonary aspergillosis[J]. Microbiol Spectr, 2022, 10(3): e0137322.
47
Huang QY, Li PC, Yue JR. Diagnostic performance of serum galactomannan and β-D-glucan for invasive aspergillosis in suspected patients: A meta-analysis[J]. Medicine (Baltimore), 2024, 103(5): e37067.
48
Zou M, Tang L, Zhao S, et al. Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis[J]. PLoS One, 2012, 7(8): e43347.
49
Çuhadar T, Kalkancı A, Tunçcan GÖ, et al. Comparison of the results of galactomannan and beta glucan antigen tests in the suspicion of invasive pulmonary aspergillosis[J]. Mikrobiyol Bul, 2023, 57(2): 274-282.
50
Komorowski AS, Hall CW, Atwal S, et al. Cerebrospinal fluid galactomannan detection for the diagnosis of central nervous system aspergillosis: a diagnostic test accuracy systematic review and meta-analysis[J]. Clin Microbiol Infect, 2024, 30(10): 1244-1253.
51
Vanderbeke L, Jacobs C, Feys S, et al. A pathology-based case series of influenza- and COVID-19-associated Pulmonary aspergillosis: the proof is in the tissue[J]. Am J Respir Crit Care Med, 2023, 208(3): 301-311.
52
Naik S, Kashyap D, Deep J, et al. Utilizing next-generation sequencing: advancements in the diagnosis of fungal infections[J]. Diagnostics (Basel), 2024, 14(15): 1664.
53
Rodino KG, Simner PJ. Status check: next-generation sequencing for infectious-disease diagnostics[J]. J Clin Invest, 2024, 134(4): e178003.
54
Niu S, Liu D, Yang Y, et al. Clinical utility of metagenomic next-generation sequencing in the diagnosis of invasive pulmonary aspergillosis in acute exacerbation of chronic obstructive pulmonary disease patients in the intensive care unit[J]. Front Cell Infect Microbiol, 2024, 14: 1397733.
55
Diao Z, Zhang Y, Chen Y, et al. Assessing the quality of metagenomic next-generation sequencing for pathogen detection in lower respiratory infections[J]. Clin Chem, 2023, 69(9): 1038-1049.
56
Liu Z, Chen H, Chen D, et al. Metagenomic next-generation sequencing for the diagnosis of invasive pulmonary aspergillosis in type 2 diabetes mellitus patients[J]. Sci Rep, 2024, 14(1): 16618.
57
Xu CH, Zhang LN, Liu T, et al. Performance of Galactomannan, Aspergillus-PCR, and metagenomic sequencing for the diagnosis of invasive pulmonary aspergillosis in hematological patients[J]. J Microbiol Immunol Infect, 2025, 58(6): 743-750.
58
Han D, Diao Z, Lai H, et al. Multilaboratory assessment of metagenomic next-generation sequencing for unbiased microbe detection[J]. J Adv Res, 2022, 38: 213-222.
59
Vardakas KZ, Samonis G, Michalopoulos A, et al. Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials[J]. Crit Care Med, 2006, 34(4): 1216-1224.
60
Cortegiani A, Russotto V, Maggiore A, et al. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients[J]. Cochrane Database Syst Rev, 2016, 2016(1): CD004920.
61
Bartalucci C, Mezzogori L, Schiavoni R, et al. Antifungal treatment strategies in intensive care unit patients[J]. Eur J Clin Invest, 2026, 56(1): e70177.
62
Hatzl S, Reisinger AC, Posch F, et al. Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients: an observational study[J]. Crit Care, 2021, 25(1): 335.
63
Sprute R, Nacov JA, Neofytos D, et al. Antifungal prophylaxis and pre-emptive therapy: when and how?[J]. Mol Aspects Med, 2023, 92: 101190.
64
Hosseini-Moghaddam SM, Chaparro C, Luong ML, et al. The effectiveness of culture-directed preemptive anti-Aspergillus treatment in lung transplant recipients at one year after transplant[J]. Transplantation, 2015, 99(11): 2387-2393.
65
Chang A, Musk M, Lavender M, et al. Epidemiology of invasive fungal infections in lung transplant recipients in Western Australia[J]. Transpl Infect Dis, 2019, 21(3): e13085.
66
Baker AW, Maziarz EK, Arnold CJ, et al. Invasive fungal infection after lung transplantation: epidemiology in the setting of antifungal prophylaxis[J]. Clin Infect Dis, 2020, 70(1): 30-39.
67
Pennington KM, Dykhoff HJ, Yao X, et al. The impact of antifungal prophylaxis in lung transplant recipients[J]. Ann Am Thorac Soc, 2021, 18(3): 468-476.
68
Hunter CJ, Chou A, Roeder H, et al. Isavuconazole provides effective and tolerable antifungal prophylaxis for patients with acute myeloid leukemia[J]. Leuk Res, 2026, 160: 108144.
69
Ju C, Lian Q, Wang X, et al. Efficacy of different durations of antifungal prophylaxis with nebulized amphotericin B after lung transplantation: a retrospective cohort study[J]. J Thorac Dis, 2023, 15(10): 5396-5404.
70
Wang Y, Xie J, Xing Y, et al. Choosing optimal antifungal agents to prevent fungal infections in nonneutropenic critically ill patients: trial sequential analysis, network Meta-analysis, and pharmacoeconomic analysis[J]. Antimicrob Agents Chemother, 2017, 61(12): e00620-17.
71
Albakri SA, Aljabri AK, Alharbi EA, et al. Effectiveness and safety of empirical antifungal strategies in critically ill, non-neutropenic patients: a multi-center observational study[J]. Infect Drug Resist, 2026, 19: 579631.
72
Chen Y, Zhao J, Wang Y, et al. The efficacy and safety of first-line monotherapies in primary therapy of invasive aspergillosis: a systematic review[J]. Front Pharmacol, 2025, 15: 1530999.
73
Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial[J]. Lancet, 2016, 387(10020): 760-769.
74
Liu A, Xiong L, Wang L, et al. Compare the efficacy of antifungal agents as primary therapy for invasive aspergillosis: a network meta-analysis[J]. BMC Infect Dis, 2024, 24(1): 581.
75
Gu Q, Chen Y, Ding P, et al. Antifungal treatment regimens as primary therapy for invasive aspergillosis: a systematic review and network Meta-analysis[J]. Drugs, 2026, 86(6): 927-941.
76
张婷婷, 孙玲洁, 冯四洲, 等. 艾沙康唑治疗侵袭性真菌病的临床研究进展[J].中国感染与化疗杂志, 2022, 22(3): 360-365.
77
Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial[J]. Ann Intern Med, 2015, 162(2): 81-89.
78
McCarthy MW, Petraitis V, Walsh TJ. Combination therapy for the treatment of pulmonary mold infections[J]. Expert Rev Respir Med, 2017, 11(6): 481-489.
79
Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis[J]. Lancet Infect Dis, 2016, 16(7): 828-837.
80
Salmanton-García J, Seidel D, Koehler P, et al. Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn)[J]. J Antimicrob Chemother, 2019, 74(11): 3315-3327.
81
Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases[J]. Clin Infect Dis, 2005, 41(5): 634-653.
82
Powell C, Puig CA, Saddoughi SA, et al. Pulmonary mucormycosis: outcomes by treatment modality and underlying comorbidity[J]. Ann Thorac Surg, 2026, 122(2): 311-319.
83
Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper[J]. Intensive Care Med, 2020, 46(6): 1127-1153.
84
Roberts JA, Sime FB, Lipman J, et al. Are contemporary antifungal doses sufficient for critically ill patients? Outcomes from an international, multicenter pharmacokinetics study for Screening Antifungal Exposure in Intensive Care Units-the SAFE-ICU study[J]. Intensive Care Med, 2025, 51(2): 302-317.
85
Roger C. Understanding antimicrobial pharmacokinetics in critically ill patients to optimize antimicrobial therapy: a narrative review[J]. J Intensive Med, 2024, 4(3): 287-298.
86
Hanai Y, Hamada Y, Kimura T, et al. Favorable effects of voriconazole trough concentrations exceeding 1 μg/ml on treatment success and all-cause mortality: a systematic review and meta-analysis[J]. J Fungi (Basel), 2021, 7(4): 306.
87
Sanz-Codina M, Bozkir HÖ, Jorda A, et al. Individualized antimicrobial dose optimization: a systematic review and meta-analysis of randomized controlled trials[J]. Clin Microbiol Infect, 2023, 29(7): 845-857.
88
McCreary EK, Davis MR, Narayanan N, et al. Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases Pharmacists: Endorsed by the Mycoses Study Group Education and Research Consortium[J]. Pharmacotherapy, 2023, 43(10): 1043-1050.
89
Chastain DB, Anderson DT, Eudy J, et al. Precision dosing of systemic antifungals in adults: therapeutic drug monitoring, empiric dose optimization and barriers to implementation[J]. J Antimicrob Chemother, 2026, 81(3): dkag055.
No related articles found!
阅读次数
全文


摘要


AI
小
编
AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?